Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D07HVY
|
|||
Former ID |
DAP000709
|
|||
Drug Name |
Efavirenz
|
|||
Synonyms |
EFV; EFZ; Eravirenz; Stocrin; Sustiva; DMP 266; L 743726; DMP-266; L-741211; L-743725; L-743726; Stocrin (TN); Strocin (TM); Sustiva (TM); Sustiva (TN); Efavirenz (JAN/INN); L-743,726; Zoxazin-2-one; Efavirenz, (S)-isomer; Met-SDF-1.beta. & Efavirenz; Met-Stromal Cell-derived Factor-1.beta. (Human) & Efavirenz; (-)-Efavirenz; (4S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one; (4S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one; (4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one; (4S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one; (S)-6-Chloro-4-(2-cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-ben; (S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one; (S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one; 2H-3,1-Benzoxazin-2-one, 6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (4S)-(9; 6-chloro-4-(2-cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Human immunodeficiency virus infection [ICD-11: 1C62; ICD-9: 279.3] | Approved | [1] | |
Therapeutic Class |
Anti-HIV Agents
|
|||
Structure |
Download2D MOL |
|||
Formula |
C14H9ClF3NO2
|
|||
Canonical SMILES |
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F
|
|||
InChI |
1S/C14H9ClF3NO2/c15-9-3-4-11-10(7-9)13(14(16,17)18,21-12(20)19-11)6-5-8-1-2-8/h3-4,7-8H,1-2H2,(H,19,20)/t13-/m0/s1
|
|||
InChIKey |
XPOQHMRABVBWPR-ZDUSSCGKSA-N
|
|||
CAS Number |
CAS 154598-52-4
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
10288, 615076, 644086, 819805, 819816, 822777, 822778, 823557, 2102933, 7847960, 7887287, 7979148, 8032270, 8189153, 12014858, 14850291, 26719858, 43121048, 46386724, 46392227, 46392228, 46506827, 49681705, 50064506, 53788925, 57315036, 78192089, 87350529, 91146581, 92308418, 92309272, 92717165, 93166541, 99444180, 104234240, 104330198, 118313744, 124658998, 126592964, 126608811, 126622440, 126654055, 129722732, 131300250, 134337998, 135022248, 136367956, 136903808, 137005170, 137229934
|
|||
ChEBI ID |
CHEBI:119486
|
|||
ADReCS Drug ID | BADD_D00749 | |||
SuperDrug ATC ID |
J05AG03
|
|||
SuperDrug CAS ID |
cas=154598524
|
Interaction between the Drug and Microbe | Top | |||
---|---|---|---|---|
The Abundace of Studied Microbe(s) Regulated by Drug | ||||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
Studied Microbe: Bacteroides fragilis enterotoxigenic
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bacteroides fragilis enterotoxigenic was decreased by Efavirenz (adjusted p-values: 3.05E-03). | |||
Studied Microbe: Bacteroides fragilis nontoxigenic
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bacteroides fragilis nontoxigenic was decreased by Efavirenz (adjusted p-values: 6.27E-05). | |||
Studied Microbe: Bacteroides uniformis
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bacteroides uniformis was decreased by Efavirenz (adjusted p-values: 2.42E-03). | |||
Studied Microbe: Bacteroides vulgatus
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bacteroides vulgatus was decreased by Efavirenz (adjusted p-values: 9.73E-03). | |||
Studied Microbe: Odoribacter splanchnicus
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Odoribacter splanchnicus was decreased by Efavirenz (adjusted p-values: 6.09E-03). | |||
Studied Microbe: Parabacteroides distasonis
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Parabacteroides distasonis was decreased by Efavirenz (adjusted p-values: 1.03E-05). | |||
Studied Microbe: Parabacteroides merdae
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Parabacteroides merdae was decreased by Efavirenz (adjusted p-values: 3.12E-05). | |||
Studied Microbe: Prevotella copri
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Prevotella copri was decreased by Efavirenz (adjusted p-values: 1.75E-03). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
Studied Microbe: Eubacterium rectale
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Eubacterium rectale was decreased by Efavirenz (adjusted p-values: 5.07E-03). | |||
Studied Microbe: Ruminococcus bromii
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Ruminococcus bromii was decreased by Efavirenz (adjusted p-values: 2.03E-04). |
Drug Resistance Mutation (DRM) | Top | |||
---|---|---|---|---|
DRM | DRM Info |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Human immunodeficiency virus Reverse transcriptase (HIV RT) | Target Info | Modulator | [3] |
References | Top | |||
---|---|---|---|---|
REF 1 | Approved antiretroviral drugs. Antiretroviral Drugs. Company report of AVERT. 2009. | |||
REF 2 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.